Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14813528 | 0.81 | ALDH1A1 (0.45) | ALDH1A1GAA | |
| SCHEMBL2023366 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2HSD17B10DRD4KDM4EALDH1A1 | |
| SCHEMBL4513476 | 0.80 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL17986061 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2HSD17B10DRD4KDM4EALDH1A1 | |
| SCHEMBL30164149 | 0.76 | OPRD1 (0.35) | KDM4EALDH1A1POLB | |
| SCHEMBL29232157 | 0.76 | OPRD1 (0.35) | KDM4EALDH1A1POLB | |
| SCHEMBL21150506 | 0.75 | CTSK (0.39) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20305061 | 0.74 | HDAC1 (0.53) | SMN1; SMN2KDM4EALDH1A1POLBMAPT | |
| SCHEMBL18291493 | 0.73 | GPR119 (0.38) | — | |
| SCHEMBL9937728 | 0.72 | CTSK (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAPK4 | SMN1; SMN2 3757/4885HSD17B10 4078/4885DRD4 1221/4885 |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | MAPK1, MAPKAPK2, MAPKAPK5 | SMN1; SMN2 3749/4885HSD17B10 4054/4885DRD4 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.